Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 5/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27976262 | 0.85 | TAS2R14 (0.49) | TAS2R14CTSSDHODHHDAC6LMNA | |
| SCHEMBL28036053 | 0.85 | TAS2R14 (0.49) | TAS2R14CTSSDHODHHDAC6LMNA | |
| SCHEMBL28327188 | 0.85 | TAS2R14 (0.49) | TAS2R14CTSSDHODHHDAC6LMNA | |
| SCHEMBL45490 | 0.84 | LMNA (0.59) | LMNAGAATSHRCFTRPDK2 | |
| SCHEMBL1508457 | 0.83 | LMNA (0.50) | TAS2R14CTSSLMNAGAATSHR | |
| SCHEMBL5239843 | 0.83 | CTSS (0.51) | TAS2R14CTSSLMNAGAATSHR | |
| SCHEMBL28052031 | 0.82 | TAS2R14 (0.55) | TAS2R14CTSSDHODHHDAC6LMNA | |
| SCHEMBL3531721 | 0.81 | CFTR (0.51) | TAS2R14CTSSLMNAGAATSHR | |
| SCHEMBL10391427 | 0.81 | LMNA (0.45) | TAS2R14LMNAGAATSHRCFTR | |
| SCHEMBL4119115 | 0.81 | CTSS (0.56) | TAS2R14CTSSLMNAGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| EP-4602028-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250136590-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025067227-A1 | PREPARATION METHOD FOR CBL-B REGULATOR, AND USE | 浙江华海药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| WO-2012150202-A1 | ISOINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | WO | disclosed |
| US-20120283271-A1 | ISOINDOLINONE DERIVATIVES | BERTHEL STEVEN JOSEPH (US) | 2012-11-08 | — | — | US | disclosed |
| EP-2432321-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| WO-2010135504-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135504-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | TAS2R14 4173/4885CTSS 2833/4885DHODH 2605/4885 |
| US-20120283271-A1 | ISOINDOLINONE DERIVATIVES | GCK, GCKR, PDK2 | TAS2R14 3818/4885CTSS 1858/4885DHODH 1028/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | TAS2R14 4755/4885CTSS 874/4885DHODH 3032/4885 |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | TAS2R14 4317/4885CTSS 1818/4885DHODH 2481/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | TAS2R14 4229/4885CTSS 3411/4885DHODH 2951/4885 |
| US-20250136590-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | TAS2R14 4382/4885CTSS 1175/4885DHODH 3718/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | TAS2R14 3597/4885CTSS 722/4885DHODH 3396/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | TAS2R14 4229/4885CTSS 3411/4885DHODH 2951/4885 |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CA, PI4KA | TAS2R14 3053/4885CTSS 3934/4885DHODH 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.